Alerta

MICELLAR NANOPARTICLES AND USES THEREOF

Resumen de: EP4603589A2

The present disclosure includes cationic carrier units comprising (i) a water soluble polymer, (ii) a positively charged carrier, and (iii) an adjuvant moiety, wherein when the cationic carrier unit is mixed with an anionic payload (e.g., an antisense oligonucleotide) that electrostatically interacts with the cationic carrier unit, the resulting composition self-organizes into a micelle encapsulating the anionic payload in its core. The cationic carrier units can also comprise a tissue specific targeting moiety, which would be displayed on the surface of the micelle. The disclosure also includes micelles comprising the cationic carrier units of the disclosure, methods of manufacture of cationic carrier units and micelles, pharmaceutical compositions comprising the micelles, and also methods of treating diseases or conditions comprising administering the micelles to a subject in need thereof.

LIPID-POLYMER COMPOUNDS, COMPOSITIONS, AND USES THEREOF

Resumen de: WO2024081668A2

Described herein are compounds comprising a lipid connected to a backbone of a polymer with functional groups. Also described herein is the use of such reagents for delivering nucleic acids to a cell.

A FORMULATION FOR ORAL DELIVERY OF PEPTIDES AND BIOSIMILARS FOR SYSTEMIC ABSORPTION AND METHOD OF MANUFACTURING THE SAME

Resumen de: WO2024079756A2

The invention relates to formulation for oral delivery of peptides and/or drug molecules and a method of manufacturing the same. The oral formulation is useful for delivering peptides to the gastrointestinal tract, preferably at the ileo-caecal junction of colon.

NOVEL TUMOR-SPECIFIC ANTIGENS FOR MYELOID LEUKEMIA AND USES THEREOF

Resumen de: WO2024077376A1

Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) shared by a large proportion of AML cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of myelodysplastic syndrome (MDS) or leukemia such as AML is also described.

LIPID NANOPARTICLE FORMULATIONS FOR MRNA DELIVERY TO LANGERHANS CELLS

Resumen de: AU2023361222A1

The present invention relates to pharmaceutical compositions comprising at least one lipid nanopartide (LNP) specific for targeting Langerhans cells (LC) wherein the LNP encapsulates at least one mRNA, is capable of specifically binding to the receptor Langerin and facilitates Langerin-mediated uptake and intracellular delivery of said mRNA molecule and its translation into at least one protein or peptide. Further envisaged is the pharmaceutical composition for use in the treatment of cancer, of an autoimmune disease, of a bacterial infection, of a viral infection, of a fungal infection or of a graft-vs. host disease, of a local or systemic inflammation, of an allergy, or for hyposensitization.

HUMAN SERUM ALBUMIN BASED NANOCARRIERS FOR TARGETED IMMUNOTHERAPY

Resumen de: EP4603108A1

The present invention relates to a mannose-HSA based nanocarrier system, and a pharmaceutical composition containing the same for delivery of immunomodulatory drugs into target cells expressing surface mannose receptors. The present invention further relates to a method of manufacturing said mannoseHSA nanocarrier system.

LIPIDIC NANOPARTICLES COMPRISING AN ENCAPSULATED DRUG AND METHOD OF PRODUCING THE SAME

Resumen de: WO2024095144A1

The present application relates to lipidic nanoparticles that are suitable for the treatment of neurologic or chronic diseases. The lipidic nanoparticles of the present application are of the solid lipid nanoparticles or nanostructured lipid carriers and comprise an encapsulated drug with a sustained and controlled drug delivery in the treatment of neurologic or chronic diseases.

NOVEL IONIZABLE LIPIDS

Resumen de: MX2025004314A

The present invention relates to compounds of formula (I). The invention also extends to micro- or nanoparticles comprising a compound of formula (I). For instance, compounds of formula (I) can be used to produce stable lipid nanoparticles (LNPs). The LNPs have high encapsulation efficiency and can be used to deliver a therapeuticor prophylactic agent to a patient.

MODIFIED OLIGONUCLEOTIDES

Resumen de: AU2023360051A1

The invention relates to oligonucleotides that inhibit Toll-Like Receptor 7 (TLR7) and/or Toll-Like Receptor 8 (TLR8), or potentiate TLR8, and uses thereof.

Composiciones de nanopartículas lipídicas

Resumen de: US2025090471A1

The disclosure provides lipid nanoparticle (LNP) compositions of ionizable lipids, helper lipids, neutral lipids, and PEG lipids useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The LNP compositions disclosed herein are useful in methods of gene editing and methods of delivering a biologically active agent and methods of modifying or cleaving DNA.

一种基于CMCS封装性多孔金纳米壳对紫杉醇的增溶方法

Resumen de: CN120501719A

本发明涉及药物制剂技术领域，尤其涉及基于CMCS封装的多孔金纳米壳在紫杉醇药物输送上的应用。本技术方法为将通过CMCS封装的多孔金纳米壳作为紫杉醇药物的载体，从而能够在使用时实现对PTX的pH响应性释放。本发明提供的基于CMCS封装性多孔金纳米壳在紫杉醇药物输送上的应用，将多孔金纳米壳与紫杉醇药物混合，并通过CMCS进行封装形成的CMCS/PTX/EHGNs，能够在癌症治疗时提升其水溶性和生物利用度。

一种载有酚醛网络的白蛋白纳米粒子的制备方法及应用

Resumen de: CN120501722A

本发明适用于生物医药技术领域，提供了一种载有酚醛网络的白蛋白纳米粒子的制备方法及应用。本发明通过将表没食子儿茶素没食子酸酯‑铜(EGCG‑Cu)金属酚醛网络(EC NPs)负载于牛血清白蛋白纳米粒子(BSANPs)内，构建了一种智能纳米输送体系(BEC NPs)。该体系可特异性靶向炎症部位中性粒细胞，响应炎症微环境释放EC NPs，通过清除活性氧、抑制中性粒细胞外陷阱形成、促进巨噬细胞向M2型极化、抑制细胞焦亡等机制改善炎症微环境，缓解炎症损伤。体内实验显示BEC NPs能促进牙槽骨再生和牙周组织修复，生物相容性良好，为慢性牙周炎提供了兼具抗炎、免疫调控和组织修复功能的纳米治疗策略。

一种环状多倍串联RNA正义链

Resumen de: CN120505342A

本发明提供了一种环状多倍串联RNA正义链，其包括至少一个正义链序列和至少一个间隔序列。该环状RNA衍生自含有所有必需序列的工程化亲本DNA模板，其按以下顺序包括第一环化元件、任选地至少一个第一限制性酶识别序列、至少一个靶序列、任选地至少一个第二限制性酶识别序列和第二环化元件。该环状多倍串联RNA正义链可以结合并递送多个反义链RNA，在利用环状RNA稳定性优势的同时增加正义链和反义链的结合。

一种药物组合物及其应用

Resumen de: CN120501756A

本发明公开了一种药物组合物，其包含环状RNA以及药物递送载体。与传统线性1×siRNA和环状1×siRNA相比，本公开将正义链重复串联数量增加到包括但不限于2个以上，意外地发现显著增强了沉默效果，能够显著降低PCSK9基因的表达水平，介导PCSK9蛋白的mRNA的降解。使用纳米颗粒递送寡核苷酸，增加了稳定性，降低了免疫原性，提高了降胆固醇、减少主动脉斑块负荷、抗动脉粥样硬化的作用，且安全无明显肝肾毒性，在制备高胆固醇血症、冠心病的治疗药物方面具有广阔的应用前景。

食品级乳液纳米颗粒联合自噬抑制剂在制备抗肿瘤药物中的应用

Resumen de: CN120501721A

本发明属于生物医药及纳米技术领域，具体公开了食品级乳液纳米颗粒联合自噬抑制剂在制备抗肿瘤药物中的应用，所述食品级乳液纳米颗粒是以大豆油为基础油相，单甘油脂为乳化剂，PBS为水相混合制成的乳液纳米颗粒FLNs；所述自噬抑制剂为3‑MA。本发明利用“撑死”肿瘤细胞的策略，采用食品级乳液纳米颗粒FLNs联合自噬抑制剂3‑MA瘤内注射，实现皮下异质瘤生长及转移的有效抑制，且未发现任何明显的毒副作用，有望开发为一种基于瘤内注射的安全高效抗肿瘤策略。

一种靶向型白蛋白球形核酸药物及其制备方法和使用方法

Resumen de: CN118986929A

The invention belongs to the field of research and development of tumor drugs, and provides a targeted albumin spherical nucleic acid drug for delivering a hydrophobic drug, aiming at solving the problems that the existing traditional albumin drug is poor in targeted enrichment, strong in systemic side effect and the like, and the targeted albumin spherical nucleic acid drug is characterized in that a hydrophobic molecule is wrapped in albumin (HSA), and meanwhile, the hydrophobic molecule is used as a spherical nucleic acid drug for delivering the hydrophobic drug. Albumin with a plurality of hydrophobic structural domains on the surface and a plurality of aptamer sequences (Apt) with hydrophobic groups at the 5'end are mutually non-covalently modified and combined through hydrophobic interaction to form a spherical nucleic acid structure, and the aptamer has specific targeting property. The invention also provides a preparation method and a use method of the spherical nucleic acid medicine. The drug provided by the invention has excellent targeting property and stability, can realize specific targeting delivery of different types of tumors, improves the treatment effect of the drug, reduces toxic and side effects, and is suitable for large-scale industrial application.

一种环状RNA的制备方法

Resumen de: CN120505341A

本发明提供了一种环状RNA的制备方法，包括：使用包含至少一种RNA聚合酶启动子和核酸构建体的表达载体转化宿主细胞，其中所述核酸构建体按以下顺序从5’到3’的方向包括第一环化元件、任选地至少一个第一限制性酶识别序列、至少一个靶序列、任选地至少一个第二限制性酶识别序列和第二环化元件。该方法得到的环状RNA产量高，免疫原性低，可以结合并递送多个反义链RNA。

一种乌力地格抑菌凝胶及其制备方法

Resumen de: CN120501702A

本发明涉及妇科抑菌凝胶技术领域，具体涉及一种乌力地格抑菌凝胶及其制备方法；按重量份计包括以下组分：醋酸氯己定1‑3份、梅花草提取物4‑8份、卡波姆0.8‑1.2份、三乙醇胺0.4‑0.6份、促渗剂0.5‑1.5份、改性纳米银0.04‑0.07份、甘油5‑8份、氢化聚异丁烯0.03‑0.07份、依地酸二钠0.1‑0.3份和纯化水余量，本发明采用醋酸氯己定与梅花草乙醇提取物以1：(2.5‑4)的比例复配，梅花草中的黄酮和多酚类物质可破坏微生物细胞膜通透性，促进醋酸氯己定进入菌体内部，显著降低最小抑菌浓度。

ＤＮＡ結合タンパク質を含む脂質ナノ粒子

Resumen de: AU2023326249A1

The present disclosure relates to lipid nanoparticles for delivery of DNA, the lipid nanoparticle comprising therein a DNA-binding protein or peptide bound to the DNA, and uses thereof.

がんにおけるフェロトーシス誘導剤としての高密度リポタンパク質様ナノ粒子

Resumen de: MX2022003239A

Disclosed herein are compositions and methods for treating a subject having cancer and other ferroptosis disorders with high density lipoprotein-like nanoparticles that induce ferroptosis.

ステロール系イオン化脂質及びそれを含む脂質ナノ粒子

Resumen de: CN119816292A

Compounds, compositions, and methods for delivering therapeutic, diagnostic, or prophylactic agents (e.g., nucleic acids) are described.

免疫グロブリンプロテアーゼおよびその融合体に関する組成物および方法

Resumen de: AU2023321906A1

Provided herein are compositions and methods related to compositions comprising an Ig protease fusion protein. Also provided herein are compositions and methods for therapeutic treatment, such as of autoimmune diseases, allergies, or other immunological disorders, or in combination with the administration of another therapeutic, with such Ig protease fusion protein.

癌のための新規抗原及びその用途

Resumen de: CN119816515A

Breast cancer is now the most common cancer in the world, and despite treatment progression in decades in the past, metastatic breast cancer is still a disease which cannot be cured. Novel tumor specific antigens (TSA) and tumor associated antigens (TAA) expressed by breast tumor cells are described herein. Synthetic long peptides, nucleic acids, compositions, cells, TCRs, antibodies, and vaccines derived from these TSAs and TAAs are described. The use of the TSA/TAAs, nucleic acids, compositions, antibodies, cells and vaccines for the prevention or treatment of breast cancer, including triple negative breast cancer (TNBC), is also described.

一种三重协同调控的多功能复合纳米酶的制备方法

Resumen de: CN120478633A

本发明适用于生物医学技术领域，提供了一种三重协同调控的多功能复合纳米酶的制备方法，该方法构建了一种基于三重环境自适应调控机制的智能纳米酶体系AgAu C‑L。该体系通过AgAu纳米笼的光热效应精准优化催化反应温度，同时结合罗伊氏乳杆菌的益生菌代谢特性主动降低局部pH至CeO2最佳活性范围，并协同AgAu@CeO2异质结界面电子转移优化策略增强电荷传递效率，三者共同作用显著提升CeO2纳米酶在生理中性/弱碱性环境下的催化效能，特别是其过氧化物酶样活性。该智能体系不仅能高效物理清除牙周致病菌生物膜，更能通过精准干扰病原菌核苷酸合成与精氨酸代谢等关键通路瓦解微生物协同网络，最终实现口腔微生态平衡的重塑。

一种双靶向仿生水滑石无机纳米颗粒及其制备方法和应用

Nº publicación: CN120478303A 15/08/2025

Solicitante:

浙江大学

Resumen de: CN120478303A

本发明涉及一种双靶向仿生水滑石无机纳米颗粒及其制备方法和应用，包括：获取新鲜红细胞膜；获取衰老红细胞膜；将新鲜红细胞膜和衰老红细胞膜以一定的比例加入水滑石无机纳米颗粒中进行混合搅拌，离心得到仿生水滑石无机纳米颗粒。本发明的有益效果是：本发明双靶向仿生水滑石无机纳米颗粒具有平衡递送至肝实质细胞和肝巨噬细胞的双靶向能力，可同时缓解氧化应激和炎症反应。